The United States of America has approved a new treatment against migraines, the specialty of which is that it is administered through a nasal spray, the pharmaceutical giant Pfizer announced this Friday.

This treatment, which will be marketed under the name Zavzpret, has been approved by the United States Food and Drug Administration (FDA) for treatment of severe migraine in adults.

In a large clinical trial, the results of which were published last month in scientific journal Lancet Neurologythe drug has shown positive pain-relieving effects greater than those of a placebo, sometimes as long as 15 minutes after a dose, according to Pfizer.

“One of the most important characteristics of an acute treatment option is how quickly it works,” said Kathleen Mullin of the New England Neurology and Headache Institute, quoted in a Pfizer statement.

“As a rapidly absorbed nasal spray, Zavzpret offers an alternative treatment option for those who need relief and cannot take oral medications due to nausea or vomiting,” added.

The migraines can have a significant impact on daily life and are often accompanied by with headaches, visual disturbances or light intolerance.

Pfizer said the treatment will be available in US pharmacies in July 2023.